Showing 25 to 36 of 54 results
Nasal Spray Shows Promise in Reducing Alzheimer's Brain Inflammation
Joe Walsh, an Alzheimer's patient, received an experimental nasal spray, foralumab, showing reduced brain inflammation without serious side effects; a larger clinical trial is planned.
Nasal Spray Shows Promise in Reducing Alzheimer's Brain Inflammation
Joe Walsh, an Alzheimer's patient, received an experimental nasal spray, foralumab, showing reduced brain inflammation without serious side effects; a larger clinical trial is planned.
Progress
36% Bias Score
Immunotherapy Shows 80% Success Rate in Treating Various Cancers
A Memorial Sloan Kettering study published in The New England Journal of Medicine reveals that immunotherapy successfully treated 80% of patients with various cancer types, including 100% of rectal cancer patients, offering a less toxic alternative to traditional treatments.
Immunotherapy Shows 80% Success Rate in Treating Various Cancers
A Memorial Sloan Kettering study published in The New England Journal of Medicine reveals that immunotherapy successfully treated 80% of patients with various cancer types, including 100% of rectal cancer patients, offering a less toxic alternative to traditional treatments.
Progress
52% Bias Score
Immunotherapy Shows Promise in Treating Mismatch Repair Deficient Cancers
A clinical trial at Memorial Sloan Kettering showed that immunotherapy was highly effective in treating mismatch repair deficient (MMRd) cancers, potentially eliminating the need for surgery, chemotherapy, and radiation for many patients, significantly improving quality of life.
Immunotherapy Shows Promise in Treating Mismatch Repair Deficient Cancers
A clinical trial at Memorial Sloan Kettering showed that immunotherapy was highly effective in treating mismatch repair deficient (MMRd) cancers, potentially eliminating the need for surgery, chemotherapy, and radiation for many patients, significantly improving quality of life.
Progress
44% Bias Score
NHS Fast-Tracks Melanoma Vaccine Access
The NHS will provide fast-tracked access to a new melanoma vaccine, iSCIB1+, for advanced melanoma patients in England, aiming to prevent recurrence and potentially saving lives; up to 10,000 patients will receive personalized cancer treatments by 2030.
NHS Fast-Tracks Melanoma Vaccine Access
The NHS will provide fast-tracked access to a new melanoma vaccine, iSCIB1+, for advanced melanoma patients in England, aiming to prevent recurrence and potentially saving lives; up to 10,000 patients will receive personalized cancer treatments by 2030.
Progress
48% Bias Score
Long Covid Clinical Trial Aids Patient's Return to Work
A clinical trial at Glenfield Hospital in Leicester helped a 64-year-old woman with long Covid return to work after an eight-week exercise program that improved her fitness and reduced fatigue; the study involved 181 patients and showed improvements in exercise capacity and immune function, but a la...
Long Covid Clinical Trial Aids Patient's Return to Work
A clinical trial at Glenfield Hospital in Leicester helped a 64-year-old woman with long Covid return to work after an eight-week exercise program that improved her fitness and reduced fatigue; the study involved 181 patients and showed improvements in exercise capacity and immune function, but a la...
Progress
44% Bias Score
Puberty Blockers for Gender Dysphoria: Clinical Trial Proposed Amidst Controversy
Due to insufficient evidence, routine use of puberty blockers for gender dysphoria in children was halted; a clinical trial is proposed to assess potential benefits and harms, addressing polarized views and a lack of robust data.
Puberty Blockers for Gender Dysphoria: Clinical Trial Proposed Amidst Controversy
Due to insufficient evidence, routine use of puberty blockers for gender dysphoria in children was halted; a clinical trial is proposed to assess potential benefits and harms, addressing polarized views and a lack of robust data.
Progress
60% Bias Score
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Progress
52% Bias Score
Immunotherapy Shows Promise in Treating MMR-deficient Solid Tumors
A clinical trial at Memorial Sloan Kettering Cancer Center showed that an immunotherapy treatment led to complete tumor disappearance in all 49 rectal cancer patients and 65% of other cancer patients with a specific genetic mutation (MMR-deficient), avoiding the need for surgery, radiation, and chem...
Immunotherapy Shows Promise in Treating MMR-deficient Solid Tumors
A clinical trial at Memorial Sloan Kettering Cancer Center showed that an immunotherapy treatment led to complete tumor disappearance in all 49 rectal cancer patients and 65% of other cancer patients with a specific genetic mutation (MMR-deficient), avoiding the need for surgery, radiation, and chem...
Progress
40% Bias Score
Stem-Cell Transplants Show Promise in Parkinson's Treatment
Two small studies revealed stem-cell transplants significantly eased Parkinson's symptoms in patients, with one showing a 20-point improvement on a standard scale; the FDA approved one treatment for a final-stage trial before potential approval, offering hope for the 1 million Americans with this di...
Stem-Cell Transplants Show Promise in Parkinson's Treatment
Two small studies revealed stem-cell transplants significantly eased Parkinson's symptoms in patients, with one showing a 20-point improvement on a standard scale; the FDA approved one treatment for a final-stage trial before potential approval, offering hope for the 1 million Americans with this di...
Progress
44% Bias Score
AI Therapy Bots Show Comparable Efficacy to Human Clinicians in Randomized Clinical Trial
A Dartmouth College study published in the New England Journal of Medicine found that AI bots, after rigorous training, provide mental health therapy as effectively as human clinicians, showing significant improvement in roughly 200 participants with depression, anxiety, or eating disorders, offerin...
AI Therapy Bots Show Comparable Efficacy to Human Clinicians in Randomized Clinical Trial
A Dartmouth College study published in the New England Journal of Medicine found that AI bots, after rigorous training, provide mental health therapy as effectively as human clinicians, showing significant improvement in roughly 200 participants with depression, anxiety, or eating disorders, offerin...
Progress
44% Bias Score
Gantenerumab Halves Alzheimer's Risk in High-Risk Individuals
A Washington University study found that eight years of gantenerumab treatment halved the risk of Alzheimer's in 22 genetically predisposed individuals, highlighting potential for preventative treatment, but longer-term studies and broader trials are needed.
Gantenerumab Halves Alzheimer's Risk in High-Risk Individuals
A Washington University study found that eight years of gantenerumab treatment halved the risk of Alzheimer's in 22 genetically predisposed individuals, highlighting potential for preventative treatment, but longer-term studies and broader trials are needed.
Progress
44% Bias Score
Deep Brain Stimulation Trial for Alcohol and Opioid Addiction
A UK trial will implant electrodes in the brains of 12 alcoholic and opioid addicts to test deep brain stimulation's ability to reduce cravings and improve self-control, building on its success treating Parkinson's, depression, and OCD.
Deep Brain Stimulation Trial for Alcohol and Opioid Addiction
A UK trial will implant electrodes in the brains of 12 alcoholic and opioid addicts to test deep brain stimulation's ability to reduce cravings and improve self-control, building on its success treating Parkinson's, depression, and OCD.
Progress
40% Bias Score
Showing 25 to 36 of 54 results